Work Here?
Singular Genomics
Work Here?
Biotechnology company specializing in genomic sequencing
Singular Genomics
Work Here?
Biotechnology company specializing in genomic sequencing
About Singular Genomics
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
San Diego, California
Founded
2016
Overview
Singular Genomics focuses on advancing genomics, the study of an organism's complete set of DNA, by providing tools and technologies for genomic sequencing. Their main product, the G4 sequencing platform, is designed for ultra-high throughput and high-resolution spatial sequencing, allowing researchers to process multiple samples at once. This efficiency is crucial for conducting large-scale genomic studies. Singular Genomics serves a diverse clientele, including academic researchers, pharmaceutical companies, and clinical laboratories, who utilize their products for multiomic research, which examines various biological data types like DNA, RNA, and proteins. Unlike many competitors, Singular Genomics emphasizes high-performance sequencing technologies that support complex biological research. The company's goal is to accelerate scientific and medical research to better understand and treat complex diseases.
Simplify's Take
What believers are saying
- Acquisition by Deerfield Management provides financial backing and strategic insight for growth.
- Launch of G4X Spatial Sequencer positions Singular Genomics at the forefront of spatial sequencing.
- Significant Q4 revenue growth due to strategic expansion and new consumable kits.
What critics are saying
- Increased competition from Illumina and Element Biosciences may impact market share.
- Rapid technological advancements could render current platforms obsolete without continuous innovation.
- Potential supply chain disruptions in semiconductor components could delay production.
What makes Singular Genomics unique
- Singular Genomics offers a versatile multiomics solution with the PX Integrated Solution.
- The G4 Platform provides ultra-high throughput and high-resolution spatial sequencing capabilities.
- Partnership with Fluent Biosciences enhances scalable single-cell RNA sequencing on the G4 Platform.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$303.6M
Above
Industry Average
Funded Over
2 Rounds
Coatue ManagementBenefits
Performance Bonus
Company Equity
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 0%2 year growth
↑ 2%Singular Genomics Systems announced the closing of its acquisition by Deerfield Management for $20 per share in cash. The transaction, approved by shareholders on February 19, 2025, results in Singular Genomics becoming a private company. Josh Stahl is appointed CEO, with Jason Myers joining the Board. Trading of Singular's stock is suspended on Nasdaq, and delisting is requested. Drew Spaventa remains on the Board as a special advisor.
Singular Genomics Systems, Inc. has been acquired by Deerfield Management, marking a significant shift in the genomics landscape. The acquisition, announced on February 21, 2025, aligns Singular Genomics with a leading healthcare investment firm, providing financial backing and strategic insight. With a share price of $20.01 at acquisition, this move positions Singular Genomics to capitalize on the growing demand for next-generation sequencing technologies and precision medicine advancements.
Singular Genomics Systems (Nasdaq: OMIC) has agreed to be acquired by Deerfield Management Company for $20 per share in an all-cash transaction, representing a 254% premium over the last closing price before Deerfield's initial proposal on September 12, 2024. The deal, expected to close in the first half of 2025, will take Singular Genomics private. The transaction requires stockholder approval but is not subject to financing conditions.
SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC) (“Singular Genomics” or the “Company”), a company leveraging...
The non-binding acquisition proposal from Concentra Biosciences to acquire Singular Genomics for $12.00 per share in cash represents a significant premium to the current stock price.
Singular Genomics is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today
Biology & Biotech
1 Open Roles
People Also Viewed
Discover companies similar to Singular Genomics
About Singular Genomics
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
San Diego, California
Founded
2016
Singular Genomics is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today
Biology & Biotech
1 Open Roles
People Also Viewed
Discover companies similar to Singular Genomics